{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:27Z","timestamp":1791245187139,"version":"4.1.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Targeted therapies have revolutionized oncology but are accompanied by significant cardiovascular complications, with heart failure being a major dose-limiting toxicity. This review primarily focuses on heart failure induced by targeted anticancer agents, while also contextualizing findings with insights from classical chemotherapeutics and radiotherapy where they inform mechanistic understanding or combination regimen management. We detail the multifaceted pathophysiological mechanisms, which vary by drug class, including direct cardiomyocyte injury via HER2\/ErbB signaling disruption, mitochondrial dysfunction, oxidative stress, and novel pathways such as ferroptosis and autophagy dysregulation. The review evaluates strategies for risk assessment, highlighting the utility and limitations of clinical tools like Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) risk score, and acknowledges that while biomarkers and advanced imaging parameters like global longitudinal strain (GLS) are often reported to have high sensitivity for early detection, their performance can vary depending on the specific definitions of cardiotoxicity used and the clinical context. Current management paradigms are discussed, encompassing pharmacological cardioprotection, treatment modification protocols, and the safe continuation of therapy with concomitant cardiac medications. Furthermore, we explore emerging strategies from traditional natural products and gene-based therapies to advanced drug delivery systems aimed at providing targeted cardioprotection. Finally, future perspectives are outlined, focusing on personalized risk prediction through multi-omics and artificial intelligence, and the development of novel therapeutics with improved cardiovascular safety profiles. This mini review underscores the importance of a multidisciplinary cardio-oncology approach to optimize both oncological efficacy and long-term cardiovascular health for cancer patients.<\/jats:p>","DOI":"10.3389\/fphar.2026.1766603","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:36:43Z","timestamp":1770359803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Heart failure induced by cancer therapies: focus on targeted agents, mechanisms, risk prediction, and clinical management"],"prefix":"10.3389","volume":"17","author":[{"given":"Lifeng","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Emergency, Cancer Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoluan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhining","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baihan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renxian","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s12012-025-10059-7","article-title":"Hormone receptor expression and QT interval at baseline correlate with trastuzumab associated cardiotoxicity in HER2- PositiveBreast cancer patients: a prospective Study","volume":"25","author":"Abo Samra","year":"2025","journal-title":"Cardiovasc Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"30888","DOI":"10.1038\/s41598-025-02687-4","article-title":"Radiomics early assessment of post chemotherapy cardiotoxicity in cancer patients using 2D echocardiography imaging an interpretable machine learning study","volume":"15","author":"Ahmadi","year":"2025","journal-title":"Sci. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10741-025-10575-2","article-title":"Pharmacological prevention in cardio-oncology: from bench-to-bedside","volume":"31","author":"Avagimyan","year":"2025","journal-title":"Heart Fail Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"123945","DOI":"10.1016\/j.lfs.2025.123945","article-title":"The role of ferroptosis in doxorubicin-induced cardiotoxicity \u2013 an update","volume":"380","author":"Bhadra","year":"2025","journal-title":"Life Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3390\/ph18070959","article-title":"Beyond the basics: exploring pharmacokinetic interactions and safety in tyrosine-kinase inhibitor oral therapy for solid tumors","volume":"18","author":"Bud\u0103u","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.1021\/acssensors.5c01445","article-title":"Harnessing the power of a H2 O2 -Activated theranostic probe against Doxorubicin-Induced cardiotoxicity","volume":"10","author":"Cao","year":"2025","journal-title":"ACS Sens."},{"key":"B7","doi-asserted-by":"publisher","first-page":"118766","DOI":"10.1016\/j.ecoenv.2025.118766","article-title":"8:2 fluorotelomer alcohol exacerbates doxorubicin-induced cardiotoxicity and chemoresistance via aryl hydrocarbon receptor","volume":"303","author":"Chen","year":"2025","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-025-07790-2","article-title":"Cardiotoxicity induced by targeted cancer therapies: understanding the risks and developing solutions","author":"Chhabra","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"103840","DOI":"10.1016\/j.redox.2025.103840","article-title":"Activation of CISD2 as a protective strategy against doxorubicin-induced cardiotoxicity","volume":"86","author":"Chou","year":"2025","journal-title":"Redox Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.freeradbiomed.2025.08.017","article-title":"Targeting PDK4 to mitigate osimertinib-induced cardiotoxicity: insights into mitochondria-endoplasmic reticulum crosstalk and necroptosis","volume":"240","author":"Deng","year":"2025","journal-title":"Free Radic. Biol. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jaccao.2025.05.003","article-title":"Lung cancer and cardiovascular disease: common pathophysiology and treatment-emergent toxicity","volume":"7","author":"El-Rayes","year":"2025","journal-title":"JACC CardioOncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jaccao.2022.12.008","article-title":"Genetic predisposition to cardiovascular disease in patients with cancer: a clinical perspective","volume":"5","author":"Farmakis","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6745","DOI":"10.3390\/jcm11226745","article-title":"Metabolomic profiles on antiblastic cardiotoxicity: new perspectives for early diagnosis and cardioprotection","volume":"11","author":"Fazzini","year":"2022","journal-title":"JCM"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1624023","DOI":"10.3389\/fcvm.2025.1624023","article-title":"Soluble suppression of tumorigenicity-2 changes during cardiotoxic cancer treatment: a systematic review and meta-analysis","volume":"12","author":"Fazzini","year":"","journal-title":"Front. Cardiovasc. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3390\/jcm14041286","article-title":"Genetic background in patients with cancer therapy-induced cardiomyopathy","volume":"14","author":"Fazzini","year":"","journal-title":"JCM"},{"key":"B16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11897-024-00687-5","article-title":"Genetic biomarkers in heart failure: from gene panels to polygenic risk scores","volume":"21","author":"Figueiral","year":"2024","journal-title":"Curr. Heart Fail Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/medsci13030130","article-title":"Cardiotoxicity in breast cancer therapy: risks, mechanisms, and prevention strategies","volume":"13","author":"Fitrianti","year":"2025","journal-title":"Med. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2025.2576619","article-title":"Entrectinib binds to HMGB1 and activates cardiomyocyte autophagy by inhibiting OTUD5-MTORC1 signaling to induce cardiotoxicity","volume":"21","author":"Gao","year":"2025","journal-title":"Autophagy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy\u2013induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e70153","DOI":"10.1002\/ddr.70153","article-title":"Lazertinib: a cardio\u2010safer alternative to osimertinib for epidermal growth factor receptor L858R\/T790M double\u2010mutant tyrosine kinase resistant non\u2010small cell lung cancer","volume":"86","author":"Gawli","year":"2025","journal-title":"Drug Dev. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1007\/s00204-025-04159-0","article-title":"Evaluating the use of rodents as in vitro,, in vivo and ex vivo experimental models for the assessment of tyrosine kinase inhibitor-induced cardiotoxicity: a systematic review","volume":"99","author":"Gill","year":"2025","journal-title":"Arch. Toxicol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jaccao.2025.08.006","article-title":"Prospective evaluation of the cardiovascular effects of BRAF and MEK inhibitors in patients with Melanoma","volume":"7","author":"Glen","year":"2025","journal-title":"JACC CardioOncology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00520-025-09947-z","article-title":"Evaluating the role of montelukast on doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"33","author":"Gomaa","year":"2025","journal-title":"Support Care Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e084062","DOI":"10.1136\/bmj-2025-084062","article-title":"Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis","volume":"390","author":"Gomes","year":"2025","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"103843","DOI":"10.1016\/j.redox.2025.103843","article-title":"Small extracellular vesicles orchestrated pathological communications between breast cancer cells and cardiomyocytes as a novel mechanism exacerbating anthracycline cardiotoxicity by fueling ferroptosis","volume":"86","author":"Han","year":"2025","journal-title":"Redox Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"214439","DOI":"10.1016\/j.bioadv.2025.214439","article-title":"Lipoic acid-modified epirubicin liposomal system for tumor-targeted drug delivery and cardiotoxicity reduction","volume":"178","author":"Han","year":"2026","journal-title":"Biomater. Adv."},{"key":"B27","doi-asserted-by":"publisher","first-page":"17527","DOI":"10.1021\/acs.jmedchem.5c01094","article-title":"The delicate disulfide-acryloyl modification of prodrug facilitates precise albumin targeting, enhanced tumor accumulation, and reduced toxicity","volume":"68","author":"Hao","year":"2025","journal-title":"J. Med. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1038\/s41440-025-02402-w","article-title":"Effects of renin\u2013angiotensin system inhibitors in cancer patients: a systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Ishii","year":"2025","journal-title":"Hypertens. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.2147\/DDDT.S545216","article-title":"Natural products from traditional Chinese medicine: potential therapeutic agents in cancer therapy-induced cardiotoxicity","volume":"19","author":"Jin","year":"2025","journal-title":"DDDT"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.2147\/DDDT.S516457","article-title":"Analysis of cardiotoxicity and risk factors of breast cancer chemotherapy drugs: a five-year single-centre retrospective Study in early breast cancer","volume":"19","author":"Ju","year":"2025","journal-title":"DDDT"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.3390\/nu17172838","article-title":"Protective role of key micronutrients in chemotherapy-induced organ toxicity: a comprehensive review of mechanistic insights and clinical implications","volume":"17","author":"Konstantinidis","year":"2025","journal-title":"Nutrients"},{"key":"B32","doi-asserted-by":"publisher","first-page":"115397","DOI":"10.1016\/j.intimp.2025.115397","article-title":"Cancer therapy\u2013induced cardiac metabolic reprogramming: a new frontier in cardio-oncology","volume":"164","author":"Lang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6357","DOI":"10.2147\/IJN.S513336","article-title":"Strategic optimization of nanoparticle characteristics to enhance tumor targeting and Doxorubicin delivery","volume":"20","author":"Lee","year":"2025","journal-title":"IJN"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1680909","DOI":"10.3389\/fimmu.2025.1680909","article-title":"Real-world disproportionality analysis of cardiac failure associated with novel antineoplastic agents in breast cancer: a pharmacovigilance study","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12911-025-03091-8","article-title":"Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?","volume":"25","author":"Lin","year":"2025","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"B36","doi-asserted-by":"publisher","first-page":"33278","DOI":"10.1038\/s41598-025-18383-2","article-title":"FAERS based disproportionality analysis and network pharmacology investigation of doxorubicin associated drug induced cardiotoxicity","volume":"15","author":"Lu","year":"","journal-title":"Sci. Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1647080","DOI":"10.3389\/fonc.2025.1647080","article-title":"Multidisciplinary strategies to reduce radiotherapy-induced cardiotoxicity in breast cancer: surgical and technological innovations","volume":"15","author":"Lu","year":"","journal-title":"Front. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"156877","DOI":"10.1016\/j.phymed.2025.156877","article-title":"UPLC-Q-TOF-MS based investigation into the bioactive compounds and molecular mechanisms of Qishen Huanwu capsule attenuates anthracycline-induced cardiotoxicity","volume":"143","author":"Lv","year":"2025","journal-title":"Phytomedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"118490","DOI":"10.1016\/j.biopha.2025.118490","article-title":"Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models","volume":"191","author":"L\u2019Abbate","year":"2025","journal-title":"Biomed. and Pharmacother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1668308","DOI":"10.3389\/fcvm.2025.1668308","article-title":"Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches","volume":"12","author":"Migliari","year":"2025","journal-title":"Front. Cardiovasc Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e029574","DOI":"10.1161\/JAHA.123.029574","article-title":"Circulating cardiovascular biomarkers in cancer therapeutics\u2010related cardiotoxicity: review of critical challenges, solutions, and future directions","volume":"12","author":"Murtagh","year":"2023","journal-title":"JAHA"},{"key":"B42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11883-025-01336-5","article-title":"Tackling the cardio-kidney-metabolic burden in cancer","volume":"27","author":"Nahle","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","article-title":"Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy","volume":"16","author":"Negishi","year":"2023","journal-title":"JACC Cardiovasc. Imaging"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1002\/ehf2.15399","article-title":"Decoding anthracycline\u2010 and trastuzumab\u2010related cardiac dysfunction prediction: HFA\u2010ICOS scores versus strain imaging","volume":"12","author":"Nguyen","year":"2025","journal-title":"Esc. Heart Fail."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e042534","DOI":"10.1161\/JAHA.125.042534","article-title":"Vitamin C as a cardioprotective agent against doxorubicin\u2010induced cardiotoxicity","volume":"14","author":"Nsairat","year":"2025","journal-title":"JAHA"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/CIRCULATIONAHA.125.076616","article-title":"Sacubitril\/Valsartan and prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA II randomized clinical trial","volume":"152","author":"Omland","year":"2025","journal-title":"Circulation"},{"key":"B47","doi-asserted-by":"publisher","first-page":"103168","DOI":"10.1016\/j.cpcardiol.2025.103168","article-title":"HER2-targeted therapies and cardiotoxicity: from major concern to manageable risk","volume":"50","author":"Pamungkas","year":"2025","journal-title":"Curr. Problems Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2208110","DOI":"10.1155\/cdr\/2208110","article-title":"Rivaroxaban ameliorates sunitinib\u2010induced injury of cardiomyocytes via repressing MAPK signaling pathway","volume":"2025","author":"Qian","year":"2025","journal-title":"Cardiovasc. Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2025.5624","article-title":"Alteration of cardiac energetics and mitochondrial function in doxorubicin-induced cardiotoxicity: molecular mechanism and prospective implications","volume":"56","author":"Qing","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"6617","DOI":"10.3390\/ijms26146617","article-title":"PCSK9 inhibitor inclisiran attenuates cardiotoxicity induced by sequential Anthracycline and trastuzumab exposure via NLRP3 and MyD88 Pathway inhibition","volume":"26","author":"Quagliariello","year":"2025","journal-title":"IJMS"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.3390\/molecules30153311","article-title":"Doxorubicin toxicity and recent approaches to alleviating its adverse effects with focus on oxidative stress","volume":"30","author":"Radeva","year":"2025","journal-title":"Molecules"},{"key":"B52","doi-asserted-by":"publisher","first-page":"33980","DOI":"10.1038\/s41598-025-11643-1","article-title":"Vitamin B17 alleviates Sorafenib-induced cardiotoxicity in Ehrlich Ascites Carcinoma mice via modulation of inflammatory and fibrotic pathways","volume":"15","author":"Salama","year":"2025","journal-title":"Sci. Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2025.07.018","article-title":"FMO2 expression confers cardioprotection in doxorubicin therapy while preserving antitumor activity","volume":"207","author":"Sheng","year":"2025","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11306-025-02258-8","article-title":"A narrative review of metabolomics approaches in identifying biomarkers of doxorubicin-induced cardiotoxicity","volume":"21","author":"Singh","year":"2025","journal-title":"Metabolomics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.3390\/ijms26093966","article-title":"Understanding the mechanisms of chemotherapy-related cardiotoxicity employing hiPSC-Derived cardiomyocyte models for drug screening and the identification of genetic and epigenetic variants","volume":"26","author":"Solomon","year":"2025","journal-title":"IJMS"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.3390\/cancers16132419","article-title":"Prevention of anthracyclines and HER2 inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"16","author":"Sotiropoulou","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s12012-025-10037-z","article-title":"Safety of permissive cardiotoxicity of trastuzumab in patients with breast cancer: a systematic review and meta-analysis","volume":"25","author":"Taha","year":"2025","journal-title":"Cardiovasc Toxicol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s12012-025-10030-6","article-title":"Statins: novel approaches for the management of Doxorubicin-Induced Cardiotoxicity\u2014A literature review","volume":"25","author":"TamehriZadeh","year":"2025","journal-title":"Cardiovasc Toxicol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"6861","DOI":"10.1038\/s41467-025-62172-4","article-title":"Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents","volume":"16","author":"Tejay","year":"2025","journal-title":"Nat. Commun."},{"key":"B60","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.3390\/ijms26094051","article-title":"Drugs metabolism-related genes variants impact on anthracycline-based chemotherapy induced subclinical cardiotoxicity in breast cancer patients","volume":"26","author":"Vaitiekus","year":"2025","journal-title":"IJMS"},{"key":"B61","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11886-025-02283-y","article-title":"Evolving cardioprotective strategies in cardio-Oncology: a narrative review","volume":"27","author":"Wadden","year":"2025","journal-title":"Curr. Cardiol. Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1303068","DOI":"10.3389\/fonc.2024.1303068","article-title":"Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma","volume":"14","author":"Xie","year":"2024","journal-title":"Front. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jaccao.2025.05.006","article-title":"Cardiac safety of reduced cardiotoxicity surveillance during HER2-Targeted therapy","volume":"7","author":"Yu","year":"","journal-title":"JACC CardioOncology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/psp4.70087","article-title":"Mitigating trastuzumab\u2010doxorubicin cardiotoxicity with multiscale quantitative systems toxicology and PBPK\u2010Toxicodynamic predictive modeling framework","volume":"14","author":"Yu","year":"","journal-title":"CPT Pharmacom and Syst Pharma"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S1875-5364(25)60868-5","article-title":"The novel combination of astragaloside IV and formononetin protects from doxorubicin-induced cardiomyopathy by enhancing fatty acid metabolism","volume":"23","author":"Yu","year":"","journal-title":"Chin. J. Nat. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"123731","DOI":"10.1016\/j.lfs.2025.123731","article-title":"Mechanisms of aerobic exercise on doxorubicin-induced cardiomyocyte apoptosis: based on AMPK\/PI3K\/AKT signalling pathway","volume":"376","author":"Zhao","year":"2025","journal-title":"Life Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e041440","DOI":"10.1161\/JAHA.125.041440","article-title":"Ring finger protein 2 promotes oxidative stress and mitochondrial dysfunction in doxorubicin\u2010induced cardiotoxicity via the Mercaptopyruvate sulfurtransferase\/hydrogen sulfide pathway","volume":"14","author":"Zhong","year":"2025","journal-title":"JAHA"},{"key":"B68","doi-asserted-by":"publisher","first-page":"111087","DOI":"10.1016\/j.ygeno.2025.111087","article-title":"Exploring the mechanism of action of trastuzumab-induced cardiomyocyte atrophy based on the FN1\/PI3K\/AKT-mediated mTOR-independent signaling pathway","volume":"117","author":"Zhu","year":"2025","journal-title":"Genomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1766603\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:36:44Z","timestamp":1770359804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1766603\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":68,"alternative-id":["10.3389\/fphar.2026.1766603"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1766603","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"article-number":"1766603"}}